Leukocyte News and Research

RSS

Discovery 'significant step' in understanding leukaemia drug resistance

Scientists have pinpointed an enzyme responsible for breaking down and inactivating a key childhood leukaemia drug, which could help to explain why around 20 per cent of patients do not respond to therapy. Their findings are published in the Journal of Clinical Investigation.

8 Jun 2009

Metformin may 'revolutionize' cancer-fighting treatments

Researchers at McGill University and the University of Pennsylvania have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency of vaccines and cancer treatments. Their findings will be published June 3 in the journal Nature.

3 Jun 2009

Hydrogen peroxide marshals immune system

When you were a kid your mom poured it on your scraped finger to stave off infection. When you got older you might have even used it to bleach your hair. Now there's another possible function for this over-the-counter colorless liquid: your body might be using hydrogen peroxide as an envoy that marshals troops of healing cells to wounded tissue.

3 Jun 2009

Discovery of enzyme involved in inflammatory bowel disease

Researchers at Penn State College of Medicine, working with biochemists, geneticists and clinicians at the University of Bern, Switzerland and in the United Kingdom, have discovered an enzyme that has a key role in inflammatory bowel disease (IBD).

2 Jun 2009

Discovery of genetic cause for primary biliary cirrhosis

Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause.

27 May 2009

Abraxane prolongs survival in metastatic breast cancer

Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.

26 May 2009

Arthritis drug Abatacept may be effective in fighting the flu

Researchers at the University of Maryland School of Medicine have found that an approved drug for treating rheumatoid arthritis reduces severe illness and death in mice exposed to the Influenza A virus. Their findings suggest that tempering the response of the body's immune system to influenza infection may alleviate some of the more severe symptoms and even reduce mortality from this virus.

26 May 2009

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL).

20 May 2009

Discovery of mutant genes in acute lymphoblastic leukemia

A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in children, particularly because such drugs are already in clinical trials for similar blood diseases in adults.

19 May 2009

Researchers look at eczema asthma link

Many young children who get a severe skin rash develop asthma months or years later. Doctors call the progression from eczema, or atopic dermatitis, to breathing problems the atopic march. In the May 2009 issue of PLoS Biology, scientists at Washington University School of Medicine in St. Louis report another step taken towards understanding the process of atopic march.

18 May 2009

New insights into immune exhaustion

A main reason why viruses such as HIV or hepatitis C persist despite a vigorous initial immune response is exhaustion. The T cells, or white blood cells, fighting a chronic infection eventually wear out.

13 May 2009

New mathematical model predicts immune response to influenza A virus

Researchers at the University of Rochester have developed a mathematical model to predict immune responses to infection with influenza A viruses, including novel viruses such as the emergent 2009 influenza A (H1N1). This model examines the contributions of specific sets of immune cells in fighting influenza A virus.

13 May 2009

Formaldehyde exposure among industrial workers linked to greater risk of cancers of the blood and lymphatic system

Results from an ongoing study of workers employed at plants that used or produced formaldehyde continue to show a possible link between formaldehyde exposure and death from cancers of the blood and lymphatic system, particularly myeloid leukemia.

12 May 2009

Sanofi-aventis to acquire Oforta, oral chronic lymphocytic leukemia treatment

Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL.

12 May 2009

FDA approves Avastin (bevacizumab) for treatment of glioblastoma multiforme

The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standard therapy.

7 May 2009

Study reveals current multi-component vaccines may need reworking

Current strategies for designing vaccines against HIV and cancers, for instance, may enable some components in multi-component vaccines to cancel the effect of others on the immune system, eliminating their ability to provide protection, according to an article to be published shortly in the Proceedings of the National Academy of Sciences (PNAS).

7 May 2009

Drugs designed to tackle endoplasmic reticulum stress might be useful in treating heart disease

Researchers say they have evidence to explain what separates your average blood vessel plaque from those that are at high risk for triggering the development of dangerous - even fatal - blood clots.

5 May 2009

New light shed on salt-sensitive hypertension

A high salt intake has been implicated in cardiovascular disease risk for 5000 years. But salt-sensitive hypertension still remains an enigma.

4 May 2009

Researchers identify a molecular target for quinoline compounds

The full details about the molecules and mechanisms that underlie the development of autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, remain to be discovered.

30 Apr 2009

Oral delivery system for RNAi therapeutics

Researchers at the University of Massachusetts Medical School (UMMS) report on a novel approach to the delivery of small bits of genetic material in order to silence genes using "RNA interference"-and in the process, discovered a potent method of suppressing inflammation in mice similar to what occurs in a range of human diseases.

30 Apr 2009